Contact PI/Project LeaderHANSON, MAUREEN REBECCA Other PIs
Awardee OrganizationCORNELL UNIVERSITY
Description
Abstract Text
OVERALL PROJECT SUMMARY – CORNELL ME/CFS COLLABORATIVE RESEARCH CENTER
Despite the fact that an estimated 1 million people or more in the U.S. suffer from Myalgic
encephalomyelitis/chronicfatiguesyndrome (ME/CFS), remarkably little is known about the etiology of the
disease and effective therapies are lacking. ME/CFS is characterized by debilitating fatigue that is not
ameliorated by rest or due to any other medical condition, and a myriad of symptoms, including
musculoskeletal pain, headaches, cognitive difficulties orthostatic intolerance, and sleep disturbances. There
are no simple scientifically validated tests for the illness, leading to a great deal of uncertainty among clinicians
when evaluating patients who report prolonged and unexplained fatigue. Fatigue and other symptoms are
exacerbated following exertion beyond a patient's particular threshold, a hallmark symptom of ME/CFS known
as post-exertional malaise (PEM). The absence of biomarkers for the disease and the lack of available
research models for ME/CFS amplify the deficiency of research data produced in the field to date. Recent
studies implicate immune dysregulation and neuroinflammation in ME/CFS. By leveraging the experience,
capabilities and varied backgrounds of researchers from four different institutions (Cornell Ithaca, Weill Cornell
Medicine, Ithaca College, and Boyce Thompson Institute), as well as key personnel from many other
organizations, the proposed Cornell ME/CFS Collaborative Research Center will apply neuroimaging,
proteomics, metabolomics, and single cell RNA and microRNA sequencing approaches to interrogate the
underlying biomedical mechanisms that contribute ME/CFS, by thorough examination of biomarkers from
patients and controls both before and after symptom provocation through exercise. Three research projects will
seek to (1) examine oxidative stress in the brain and neuroinflammation (Project 1), (2) examine inflammatory
molecules, metabolism, and cargo of extracellular vesicle (Project 2) and (3) determine levels of gene
dysregulation across the immune system (Project 3). These three research projects are supported by two
cores; one Clinical Core (Core 1: Cornell CRC Clinical Core), which will recruit and screen patients/controls
and oversee cardiopulmonary exercise testing and a Research Core (Core 2: Integrative Data Analysis
Core), which will support CRC members with data management and bioinformatics analyses, while
assimilating data across the project components to provide an integrated view of the assayed characteristics
about ME/CFS subjects studied by the Center. All Center activities will be coordinated through an
Administrative Core, which will foster synergy and integration within the Center, while also being the platform
for collaboration with other Collaborative Research Centers and the Data Management Coordinating Center.
The Administrative Core will also be responsible for outreach activities, designed to increase awareness and
understanding of ME/CFS within the research community, health professionals, and the general public.
Public Health Relevance Statement
Myalgic encephalomyelitis/chronicfatiguesyndrome (ME/CFS) is a serious, debilitating illness for which there
is no known cause nor cure. This Center will bring together a multidisciplinary team with expertise in
neuroimaging, metabolic pathways, protein identification and quantification, exercise physiology, immunology,
gene expression, and computational analysis of large data sets. By assessing subjects at baseline and
following symptom exacerbation, the team will seek to understand the underlying pathophysiology of ME/CFS
and enhance knowledge of the lay public, patients, and health professionals concerning the disease.
National Institute of Neurological Disorders and Stroke
CFDA Code
853
DUNS Number
872612445
UEI
G56PUALJ3KT5
CCV3WG2JG248
D4H1NV4APKP3
ELS2M3C6V2S5
EQA8NBEN9WD5
FFAZGE9NH3M8
K6JRCJJXFET1
M8FBSLHASMT3
P4LRVQT1H4K5
PJUVN8AT5416
RT1JPM9UMGM5
ZBMGUAZYFGC4
ZMP8BDLJTUW9
Project Start Date
30-September-2017
Project End Date
31-August-2022
Budget Start Date
01-September-2019
Budget End Date
31-August-2020
Project Funding Information for 2019
Total Funding
$1,849,848
Direct Costs
$1,458,696
Indirect Costs
$391,152
Year
Funding IC
FY Total Cost by IC
2019
National Institute on Drug Abuse
$250,000
2019
National Heart Lung and Blood Institute
$359,244
2019
National Institute of Neurological Disorders and Stroke
$1,240,604
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5U54NS105541-03
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5U54NS105541-03
Patents
No Patents information available for 5U54NS105541-03
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5U54NS105541-03
Clinical Studies
No Clinical Studies information available for 5U54NS105541-03
News and More
Related News Releases
No news release information available for 5U54NS105541-03
History
No Historical information available for 5U54NS105541-03
Similar Projects
No Similar Projects information available for 5U54NS105541-03